News

SUMITOMO RUBBER INDUSTRIES TOP > News > 2017 > Sumitomo Rubber expands production with investment in new facility to manufacture rubber parts for medical applications in Slovenia

Sumitomo Rubber expands production with investment in new facility to manufacture rubber parts for medical applications in Slovenia

 
    
 

Sumitomo Rubber expands production with investment in new facility to manufacture rubber parts for medical applications in Slovenia

 

August 1, 2017

 

Sumitomo Rubber Industries, Ltd. (SRI) is pleased to announce that, as part of our global expansion strategy, we have made the decision to establish a new production site to manufacture rubber parts for medical applications. The investment amount for the new facility in central Slovenia, a subsidiary of Lonstroff AG in Switzerland, will be 34 million EUR(Approx. 39.8 million USD*1).

SRI has been expanding its business since it acquired Lonstroff AG (subsidiary of Lonstroff Holding AG), which produces and sells rubber parts for pharmaceutical primary packaging and rubber parts for medical applications to major pharmaceutical and medical companies in January of 2015. The start of operation of its Slovenian subsidiary is planned in April of 2019. With this investment our production capacity of primary packaging and rubber parts for medical applications will be tripled compared with 2016 in Europe. This investment is another big step in the expansion of our precision rubber parts for medical application business on a global scale.

Lonstroff Holding AG acquired Lonstroff AG as of June 30 and changed company name to Lonstroff AG and became the mother company of the new facility in Slovenia.

 

1. Profile of New company in Slovenia (Planned)

(1)Company name:Lonstroff Medical Elastomers d.o.o. (English)
Lonstroff medicinski elastomeri, d.o.o. (Slovenian)
(2)Representative:Peter Weber
(3)Head Office:To be finalized in due course
(4)Establishment of the company:August of 2017
(5)Start of Operation:April of 2019
(6)Main Business:Production of pharmaceutical primary packaging and precision rubber parts for medical use
(7)Share Capital:1 million EUR(Approx. 1.2millon USD*1)
(8)Shareholder:Lonstroff AG (after merger) 100%
(9)Investment Amount:34 million EUR(Approx. 39.8 million USD*1)
(10)Site Area:Approx. 30,000square meter
(11)Number of employees:Approx. 200


2. Profile of Lonstroff AG (after merger)

(1)Company name:Lonstroff AG
(2)Representative:Urs Bahnmuller (CEO)
(3)Head Office:Aargau, Switzerland
(4)Establishment of Lonstroff AG:1908
(5)Main Business:Production and sales of pharmaceutical primary packaging, precision rubber parts for medical use and rubber parts for industrial applications
(6)Share Capital:3.7 Million CHF(Approx. 3.8 million USD*2)
(7)Shareholder:SRI 100%
(8)Number of employees:165


*1 Exchange Rate: 1 EUR=1.17 USD*2 Exchange Rate: 1 CHF=1.03 USD

 

Previous Page